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OPEN
ORIGINAL ARTICLE
Maternal and infant infections stimulate a rapid
leukocyte response in breastmilk
Foteini Hassiotou1,2, Anna R Hepworth1, Philipp Metzger2,3, Ching Tat Lai1, Naomi Trengove1,4,
Peter E Hartmann1 and Luis Filgueira2
Breastmilk protects infants against infections; however, specific responses of breastmilk immune factors to different infections
of either the mother or the infant are not well understood. Here, we examined the baseline range of breastmilk leukocytes
and immunomodulatory biomolecules in healthy mother/infant dyads and how they are influenced by infections of the dyad.
Consistent with a greater immunological need in the early postpartum period, colostrum contained considerable numbers
of leukocytes (13–70% out of total cells) and high levels of immunoglobulins and lactoferrin. Within the first 1–2 weeks
postpartum, leukocyte numbers decreased significantly to a low baseline level in mature breastmilk (0–2%) (Po0.001). This
baseline level was maintained throughout lactation unless the mother and/or her infant became infected, when leukocyte
numbers significantly increased up to 94% leukocytes out of total cells (Po0.001). Upon recovery from the infection, baseline
values were restored. The strong leukocyte response to infection was accompanied by a more variable humoral immune
response. Exclusive breastfeeding was associated with a greater baseline level of leukocytes in mature breastmilk. Collectively,
our results suggest a strong association between the health status of the mother/infant dyad and breastmilk leukocyte levels.
This could be used as a diagnostic tool for assessment of the health status of the lactating breast as well as the breastfeeding
mother and infant.
Clinical & Translational Immunology (2013) 2, e3; doi:10.1038/cti.2013.1; published online 12 April 2013
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Through breastfeeding, the transfer of immune factors from the
mother to the infant, which had started already in utero, continues
postnatally.1,2 These maternal factors protect the infant from
infections and assist in the development of the infant’s intestinal
mucosa, gut microflora and own defences.3–5 Indeed, breastfed
infants have a lower risk of necrotizing enterocolitis, and reduced
susceptibility to gastrointestinal, respiratory and other infections
than formula-fed infants.2,3,6–10 The immunomodulatory function
of breastmilk is thought to be mediated by both cellular and bio-
chemical components, including maternal leukocytes and bio-
molecules with antimicrobial, anti-inflammatory, antioxidant and
prebiotic activities.6,9,11,12 However, the underlying mechanisms
through which these factors act to so consistently confer protection
are yet poorly understood.13,14
In addition to being a well-balanced source of amino acids
specifically serving the growth needs of the human infant, breastmilk
proteins, such as immunoglobulins and lactoferrin, exert antimicro-
bial and immunomodulatory activities, enhancing the infant’s defence
against pathogens.15 Secretory IgA (sIgA), the major human milk
immunoglobulin, confers maternal acquired immunity to the
infant.16 IgG and IgM antibodies are also present in breastmilk but
in much lower concentrations, exerting protective roles in the
infant.13 Despite variations observed in the concentrations of
immunomodulatory bioactive factors in breastmilk both within and
between women,13 the normal baseline levels under healthy
conditions and infection-stimulated responses during the course of
lactation are not well understood.
The immunoreactive biochemical factors of breastmilk are com-
plemented by maternal leukocytes, which are thought to confer active
immunity and influence the development of immunocompetence in
the infant, as well as protect the mammary gland from infection.7,17–19
Colostrum and mature breastmilk contain various cell types,
including mature epithelial cells, progenitor cells, stem cells and
leukocytes.20–22 While some are endogenous to the mammary gland,
others (for example, leukocytes) migrate to this site from the
lymphatic vessels and systemic circulation.23 Breastmilk leukocytes
are thought to be somewhat different from their blood
counterparts24–26 and to exert immunomodulatory functions in the
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infant via phagocytosis, secretion of antimicrobial factors, such as
cytokines and immunoglobulins, or antigen presentation.9,18,19,27 And
they are thought to perform these functions not only inside the
gastrointestinal tract of the infant, but also in distant tissues where
they are transferred via the systemic circulation.1,9,24
The concentrations of immune factors in breastmilk are by no
means stable. Breastmilk is a complex and dynamic fluid, with a
changing composition that responds to infant feeding28 and the stage
of lactation.14,15 Most previous studies on breastmilk leukocytes
focused on colostrum/early lactation milk, while very little is
known about the leukocyte range in mature breastmilk under
healthy conditions and how it changes together with biochemical
components in response to infections of the mother, and indeed the
infant. Evidence suggests that the health status of both the mother
and the infant may influence breastmilk cellular content,29 suggesting
an immunological link between the mothers and their breastfeeding
infants. This may partly explain the great variability of breastmilk
leukocyte content among women reported in the literature. An
additional explanation may be provided by the basic microscopy-
based leukocyte identification techniques previously utilized, which
pose limitations in the context of breastmilk leukocytes, some of
which share morphological traits with mammary epithelial
subtypes.30 Thus, more accurate and consistent methodology is
needed to quantify breastmilk leukocyte content and composition,
and establish the baseline levels of immune factors in breastmilk of
healthy dyads during lactation and how these may be altered by
infection. This is a critical step to improving understanding of viral
transmission during the breastfeeding period, and how leukocytes and
other breastmilk components protect the infant.31,32 In addition to
the infant, the breast is also thought to be protected by the influx of
leukocytes to mammary infection sites.19 Therefore, the leukocyte
status of breastmilk may provide a novel means for assessing the
health status of the lactating breast, the only metabolically significant
organ in the body, without clinical tests to assess its normality. In this
context, it is of interest that similar tests are routinely used by the
dairy industry to assess the quality of bovine milk and the presence of
intramammary infection in the dairy cow.33,34 To address the question
of whether the leukocyte content of breastmilk can be used to assess
the health status of the breastfeeding dyad, we examined whether
there is a baseline range of leukocytes in mature breastmilk from
healthy dyads and how this is influenced by different infections of the
mother and/or the infant.
RESULTS
Healthy mother/infant dyads have a low baseline level of leukocytes
in breastmilk
Fluorescence-activated cell sorting (FACS) quantification of CD45
protein expression was done by an analytic gating strategy that
excluded interference by dead/dying cells and/or fat globules
(Supplementary Figure S1a). Although colostrum always contained
considerable levels of leukocytes (13.2–70.4% leukocytes of total milk
cells; 32 175–784 080 viable leukocytes per ml colostrum), these
rapidly decreased toward the end of the first week postpartum to
reach a baseline level in transitional milk (0–1.7% leukocytes of total
milk cells; 0–3450 viable leukocytes per ml milk) and mature
breastmilk (0–1.5% leukocytes of total milk cells; 0–1151 viable
leukocytes per ml milk) when both the breastfeeding mother and
infant were healthy (Figure 1a; Supplementary Figures S1a,b; Tables 1
and 2). The low baseline level of mature breastmilk leukocytes under
healthy conditions was maintained even at late lactation stages (years
2–4 postpartum) (Table 1) and was found to fluctuate within certain
limits (0–2% leukocytes of total milk cells) both between and within
individuals.
Infections of the mother/infant dyad stimulate a leukocyte
response in breastmilk
Infections of the breast, other organs or general maternal infections all
stimulated a leukocyte response in breastmilk that ranged from 0.7%
(sore breast) to 93.6% (mastitis) leukocytes of total milk cells
(Po0.001) (Figures 1b–d; Tables 1 and 2). Severe breast infections,
such as mastitis, stimulated a greater leukocyte response (Po0.001).
The effect of systemic and other organ infections on breastmilk
leukocyte content was in agreement with the observed effect of mastitis
of one breast on the breastmilk leukocyte content of the other
(mastitis-free) breast (Figure 1b). A small increase in breastmilk
leukocyte content was also observed when only the infant had an
infection, while the mother was asymptomatic (P¼ 0.046) (Figure 1b).
No difference was seen between pre- and post-infection baseline
leukocyte levels (P¼ 0.48) (Figure 1b; Supplementary Figure S1c).
Importantly, the leukocyte response to infection and recovery, as well
as transition from colostrum to transitional milk, was rapid (Figures
1a and b). In contrast to leukocytes, milk total cell and viable cell
contents did not significantly vary by health status or milk type
(Figure 1c; Table 2). However, total cell content significantly increased
(P¼ 0.002) with lactation stage (Figure 1d; Table 1). The latter did not
significantly influence % cell viability (P¼ 0.09) (Figure 1d; Table 1).
Milk leukocyte content did not significantly change after week 1
postpartum as long as the dyad was healthy (P¼ 0.36) (Figure 1d).
Leukocytes in breastmilk from women with mastitis contained
monocytes, macrophages, dendritic cells, T-helper cells, cytotoxic T
cells, natural killer cells and a small population of B lymphocytes
(Figure 2a). Infection-stimulated leukocytes contained activated cell
subsets that responded to viral antigens and PHA in culture with
increased proliferation rate and altered expression of interleukin (IL)-
6, IL-17A, interferon-g and tumor necrosis factor-a (Figures 2b and c).
Infections of the mother/infant dyad stimulate a humoral immune
response in breastmilk
In addition to breastmilk leukocyte response to maternal/infant
infection, a less consistent but often significant humoral immune
response was observed. sIgA was higher in colostrum compared with
mature breastmilk from healthy dyads (Po0.001) (Figure 3a; Tables 1
and 2). In mature breastmilk, sIgA concentration increased only
during infection of the mother and/or the infant (P¼ 0.034)
(Figure 3a; Tables 1 and 2), and this increase was stronger in organ-
specific infections (Table 3). IgG concentration was generally low
(2.8–22.9mg ml1) (Table 1), with no marked difference between
colostrum and mature breastmilk from healthy dyads (P¼ 0.71), and
marginally increased with maternal or infant infection (P¼ 0.048)
(Figure 3a; Tables 1 and 2). No difference was seen between pre- and
post-infection baseline sIgA and IgG levels (P¼ 0.37 and P¼ 0.66,
respectively). In few subjects, sIgA and/or IgG concentration was
higher in the post-recovery sample, suggesting a potential delayed
response to infection (Supplementary Figure S1d). In contrast to sIgA
and IgG, no significant changes were seen for IgM or lactoferrin with
infections (P¼ 0.61 and P¼ 0.66, respectively), although colostrum
and transitional milk concentrations were higher than in mature
breastmilk from healthy dyads (Po0.001) (Figure 3a; Tables 1 and 2).
Infant age had a profound effect on breastmilk sIgA (Po0.001), IgG
(P¼ 0.045) and lactoferrin (P¼ 0.008) concentrations (Figure 3b;
Table 1). In the data set of healthy dyads, an initial sIgA decrease from
colostrum to mature breastmilk up to around week 25 and a plateau
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until week 50 was followed by an increase in later lactation (Figure 3b).
IgG concentration was constant for the first 60 weeks postpartum,
but increased in later lactation (Figure 3b; Table 1). Lactoferrin
concentration initially decreased up to around week 25 and then
increased as lactation progressed (Figure 3b; Table 1). Involution
seemed to influence the biochemical and total cellular, but not the
leukocyte, content of breastmilk, with marked increases in these
components (Table 1).
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Figure 1 Maternal and/or infant infections stimulate a breastmilk leukocyte response. (a) Reduction of CD45þ leukocyte numbers from colostrum to a low
baseline level in transitional and mature breastmilk. A breastmilk CD45þ (green) leukocyte is shown; blue: nucleus; scale bar: 2.5mm. (b–d) Effect of
maternal or infant infections on breastmilk cells in selected examples (b), and in the overall study cohort (N¼21) (c), and changes during lactation (d)
(blue: healthy dyad; red: under infection). Local regression (loess) smoothers show the overall pattern in the data. In the mastitis example in b, the insert
shows the leukocyte content of breastmilk collected on the same expression from the other non-mastitic breast.
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Breastmilk immune response differs between infection types
Breastmilk leukocyte content was significantly higher for all infection
types compared with the healthy baseline, with the weakest response
seen for infant infections (P¼ 0.046), and the strongest response
for breast infections (Po0.001), particularly mastitis (Table 3).
A decrease in % cell viability with infection was observed only for
maternal colds (P¼ 0.025). Total breastmilk cell content increased
during breast-related infections, being associated with a stronger
leukocyte response in mastitis compared with less severe breast
infections (Table 3). Principal component analysis (PCA) demon-
strated distinctive response patterns for specific sample types. Mastitis
(N¼ 5) clustered separately from other infections, being strongly
associated with breastmilk leukocyte content (Figure 4a). Weaning
(N¼ 1) and menstruation (N¼ 1) were separate from the rest of the
healthy data set. Colostrum also tended to cluster differently from the
healthy data set (Figure 4a).
Non-exclusive breastfeeding is associated with lower baseline milk
leukocyte levels
Breastfeeding status significantly related to milk leukocyte content.
Under healthy conditions, the baseline breastmilk leukocyte content
was lower in non-exclusively breastfed infants (P¼ 0.024), the
majority of whom received breastmilk with no detectable leukocytes
(Figure 4b). The infection response in both exclusive and non-
exclusive breastfeeding dyads was such that similar leukocyte levels
were seen during infection (Figure 4b).
DISCUSSION
Breastmilk has long been known to contain leukocytes,30 but their
regulation and variation between individuals and stages of lactation
are not well established. Here, we show that mature breastmilk from
healthy mother/infant dyads retains a low baseline level of 0–2%
leukocytes during lactation. Infections of the breast, other organs or
general infections of the mother or the infant stimulate a rapid
breastmilk leukocyte response, with restoration of the baseline levels
upon recovery. We suggest that the general health status of the dyad,
recent health history, environmental factors that they are exposed to
and/or the severity of an infection determine the variation in
breastmilk leukocyte content during the healthy and infection
statuses. Other factors not considered in the present study, such as
the menstrual cycle, may also influence breastmilk leukocyte content
and warrant further investigation.
The humoral breastmilk response to infection was less consistent
and more variable than the cellular response, with sIgA and IgG
showing the most consistent humoral response. The most abundant
immunoglobulin in breastmilk was sIgA, followed by IgM and IgG,
consistent with previous literature.35–39 The variation observed in
humoral breastmilk responses to infection could be explained by a
differential response of each immunological biochemical factor to
different infections, a delayed response in some dyads/infection types,
or an underlying health condition of the mother and/or the infant
during collection of the post-recovery samples. The latter is unlikely
as no evidence for a leukocyte response was found in these post-
recovery samples. Of note, the most consistent humoral immune
response was observed during mastitis, which represents a severe
infection of the breast, and is in agreement with the strong leukocyte
response.
Indeed, mastitis recorded the highest milk leukocyte contents,
which sometimes delayed to return to baseline levels, particularly
when there was a delay in diagnosis and treatment. Mastitis is
common among breastfeeding women in early stages of lactation,Ta
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Figure 2 Mastitis-specific breastmilk leukocyte subpopulations and properties. (a) Breastmilk collected from women with mastitis contained distinct
leukocyte subpopulations, including monocytes, macrophages, T helper cells, cytotoxic T cells, NK (natural killer) cells and B cells. These cells responded
to viral antigen and PHA stimulation in vitro via increased proliferation (b) and production of cytokines (c). *Po0.05, **Po0.01.
Table 2 Statistical comparison of the levels of measured variables between milk samples grouped by type (colostrum versus mature
breastmilk from healthy mother/infant dyads) or health status of the mother/infant dyad (healthy versus under infection), taking into account
individual differences
Response Transform Healthy (mature milk)
Value
Under infection (mature milk) Colostrum
Diff P-value Diff P-value
Total cell content (per ml milk) Loge 12.8 0.3 0.271 0.5 0.326
Viable cell content (per ml milk) Loge 12.8 0.3 0.253 0.5 0.353
Leukocyte contenta (per ml milk) Loge(xþ0.5) 3.8 5.9 o0.001 7.2 o0.001
% Total cell viability (of total cells) None 97.8 1.5 0.043 2.6 0.056
% Leukocytesa (of total cells) Loge(xþ0.5) 0.25 2.5 o0.001 3.6 o0.001
sIgA (mg ml1) None 860.7 169.9 0.034 1288.5 o0.001
IgG (mg ml1) Loge 2.01 0.22 0.048 0.07 0.710
IgM (mg ml1) Loge 2.49 0.064 0.606 0.864 o0.001
Lactoferrin (g l1) None 3.41 0.08 0.658 3.88 o0.001
Abbreviation: sIgA, secretory IgA.
P-values compare each group with the ‘Healthy (mature milk)’ group.
aFor leukocyte content and percentage, the data were transformed using the additive constant 0.5 for both the square root and the log transformations owing to the zeroes in the data.57
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being associated with inadequate emptying of the breast.40–42 This can
stimulate leukocyte trafficking to the breast, explaining the high levels
of milk leukocytes detected, with distinct profiles including activated
T cells that responded to antigen stimulation via proliferation
and cytokine production. Milder breast infections showed contras-
ting breastmilk responses (Table 3). Thus, the distinct changes in
breastmilk leukocyte levels and properties during mastitis could be
used as novel diagnostic tools for this condition, in which early
diagnosis is important for a successful treatment and the maintenance
of breastfeeding for longer periods.40–42 This is often not possible due
to limited understanding of its causes, the variability in associated
microorganisms40–42 and lack of tests that assess the health status of
the lactating breast. The measurement of leukocyte content and
subtypes in breastmilk using FACS, together with assessment of milk
cytokine profile and dominant microorganisms, could be used as novel
diagnostic tools to allow fast treatment of mastitis and other breast
conditions during lactation.
Different infections showed differential effects on breastmilk
composition. Some infections related to a stronger humoral response,
while others to a stronger cellular response (Figure 4b). The latter was
particularly seen in breast infections, which in contrast to other
infections, were accompanied by an increase in total cell content.
Although in milder breast infections (sore breast and blocked duct),
non-immune cell populations contributed to the increase in total cell
content, in mastitis this increase was significantly associated with a
leukocyte response (Table 3).
In addition to maternal infection, a small but significant breastmilk
leukocyte response was observed when the infant had an infection,
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Figure 3 Maternal and/or infant infections stimulate a breastmilk humoral response. (a) Effect of maternal or infant infections on breastmilk biochemical
content (sIgA, IgG, IgM and lactoferrin) in the overall study cohort (N¼21). (b) Changes of the breastmilk biochemical content during lactation under
healthy conditions (blue) and under infection (red). Local regression (loess) smoothers show the overall pattern in the data.
Table 3 Effects of different types of infection on breastmilk cellular and biochemical composition
Response Healthy
Value
Infant only Breast-related Cold Other infections
Diff P-value Diff P-value Diff P-value Diff P-value
Total cell content (per ml milk) (loge) 12.8 0.9 0.127 0.6 0.133 0.6 0.094 0.4 0.348
Viable cell content (per ml milk) (loge) 12.8 0.9 0.123 0.6 0.143 0.6 0.085 0.4 0.345
Leukocyte contenta (per ml milk) (loge(xþ0.5)) 3.7 4.3 0.046 6.7 o0.001 6.1 o0.001 5.9 0.0004
% Total cell viability (of total cells) 97.8 0.9 0.571 1.7 0.093 2.1 0.025 0.2 0.834
% Leukocytesa (of total cells) (loge(xþ0.5)) 0.3 1.1 0.064 3.2 o0.001 2.8 o0.001 2.1 o0.001
sIgA 858 88 0.632 174 0.155 144 0.197 302 0.042
IgG (loge) 2.02 0.07 0.738 0.58 0.0003 0.04 0.758 0.12 0.481
IgM (loge) 2.49 0.21 0.474 0.05 0.796 0.02 0.913 0.16 0.493
Lactoferrin 3.4 0.2 0.638 0.1 0.787 0.1 0.654 0.1 0.766
Abbreviation: sIgA, secretory IgA.
Groups include: infant-only infection (N¼3), breast-related infection (N¼9), cold (N¼12), other organ-specific infections (eye, ear, vaginal, urinary tract and gastrointestinal infections; N¼6)
and no infection/healthy (N¼28). P-values compare infection groups with the ‘Healthy’ group.
aFor leukocyte content and percentage, the data were transformed using the additive constant 0.5 for both the square root and the log transformations owing to the zeroes obtained.57
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but the mother was asymptomatic. This finding is supported by a
recent study from Riskin et al.43 that also reported a response of
breastmilk leukocytes to active infection of nursing infants. This
further reinforces the potential of breastmilk leukocyte measurement
by FACS to be used in assessment of the health status of both the
breastfeeding mother and infant. While the mechanism behind the
leukocyte movement into the breast during an infection of the infant
is still unclear, exposure of the mother to the infant’s infection may
stimulate an immunological response in the mother that is manifested
without evident symptomatology, but which influences breastmilk
leukocyte content. A potential way for this to happen is during
breastfeeding. During a milk ejection, duct pressure increases, milk
ducts dilate and milk flows toward the nipple/baby’s mouth. As
oxytocin wears off, duct pressure decreases, milk ducts reduce in size
and milk flows backwards,44 likely together with saliva from the
baby’s mouth. This is a time when it is possible that microorganisms
from the infant could be transferred back into the breast, most likely
during a pause in suckling, stimulating a local immune response.
In addition to infection, the stage of lactation influenced breastmilk
composition. With the exception of IgG concentration, significant
decreases were seen in immunomodulatory biomolecules and leuko-
cyte content from colostrum to mature breastmilk, consistent with
previous reports.35–39 From week 2 postpartum onwards, total cell
content increased with lactation stage, but leukocyte content was
maintained at a low baseline level across lactation under healthy
conditions. This is in accordance with previous findings showing a
leukocyte change early on from colostrum to mature breastmilk,14,45–47
and with a recent study showing low levels of leukocytes in mature
breastmilk under healthy conditions in a Chinese population.48
Percentage cell viability did not change significantly across lactation,
in contrast to immunoglobulins and lactoferrin, which were
differentially affected during the course of lactation, in accordance
with previous studies.35–39 Involution milk showed marked increases
in total cell content and biochemical immune factor concentrations,
suggesting that involution influences the biochemical and total cellular,
but not the leukocyte, content of breastmilk. This is in support of the
notion that cells from the epithelial compartment mediate clearing of
apoptotic cells via phagocytosis in the involuting gland.49
Exclusive breastfeeding was associated with a higher baseline level
of leukocytes in breastmilk under healthy conditions. This may be
associated with overall suckling time on the breast, and suggests that
infants that are non-exclusively breastfed receive not only lower
breastmilk volumes, but also breastmilk that contains fewer leuko-
cytes. The higher breastmilk baseline leukocyte levels in exclusively
breastfeeding dyads may contribute to the lower incidence of
infections observed in this group, further reinforcing the protective
role of breastmilk leukocytes for the infant.3,6,9
The rapid response of breastmilk leukocytes to infections of the
mother and the infant suggests that this is a tightly regulated process
aimed at conferring additional immunological support to the infant.
In situations where individuals do not have ready access to medicine,
particularly in developing countries, breastfeeding-mediated protec-
tion may be a determining factor in infant recovery and survival.
Figure 4 Interactions between breastmilk components in relation to specific
infections, stage of lactation and exclusivity of breastfeeding. (a) Biplots
illustrating the relationships between seven breastmilk immune markers as
determined from a PCA. The first two components (PC1 and PC2) are
shown in the top plot, and the second and third components (PC2 and
PC3) are seen in the middle plot. The combination of these two plots
provides a three-dimensional representation of the multivariate data. Dots
illustrate the individual records, and the vectors indicate the relative
weights of the markers on each of the principal components. Vector labels
include: ‘Leukocyte’: leukocytes per ml milk, ‘total cell’: total cells per ml
milk, ‘c’: colostrum, ‘’: healthy, ‘M’: mastitis, ‘R’: recovering mastitis, ‘B’:
other breast conditions, ‘eye’ and ‘ear’: maternal eye and ear infections,
respectively, ‘W’: weaning, ‘P’: periods, ‘T’: vaginal thrush, ‘s’: other
infections of the mother or baby. Red lines show the relative weights of
each of the measures on each of the components. (b) Effect of breast-
feeding status (exclusive, non-exclusive) on milk leukocyte content under
healthy and infection conditions.
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Formula does not offer this protection and the ability to adjust to
infant needs. Thus, these findings present new information that is
relevant to updating public policy on early infant nutrition that
maximizes immunological development and protection against infec-
tions. At the same time, they offer new grounds for examining the
mechanisms behind the very low rates of symptomatic HIV and
cytomegalovirus disease in infants exclusively breastfed by infected
mothers despite exposure to virus-infected breastmilk leukocytes.31,32
This suggests that the breast is a mucosal site preferentially sheltered
from viral replication and/or the presence of anti-viral transmission
agents in breastmilk that confer enhanced local virologic control and
protection to the infant.25 Future examination of these hypotheses
and the immunological response of the cellular and biochemical
components of breastmilk to mother HIV are warranted.
The lactating breast, being the only metabolically significant organ
of the body, for which a medical test does not exist, is often subjected
to infections, which are diagnosed late, misdiagnosed or remain
untreated. This contributes to an early cessation of breastfeeding with
adverse effects for both the mother and the infant. The detection of
breastmilk leukocyte levels may be useful in the assessment of the
health status of the lactating breast, and the breastfeeding woman and
infant. Similar tests are routinely used by the dairy industry to assess
the quality of bovine milk based on the detection of an increase in
somatic cell count being indicative of intramammary infection
(California mastitis test).33,34 Our studies have further refined and
extended this test to human lactation by demonstrating a specific
increase in breastmilk leukocytes with infection of the breastfeeding
mother and/or infant. The diagnostic potential of this method will be
reinforced by establishment of associations between specific infections
and milk leukocyte/biochemical composition. This could prove
particularly useful in early, rapid and successful diagnosis of these
infections and the underlying microorganism(s) as well as in assessing
the effectiveness of a treatment. In addition, our data provide the
basis for investigating the effect of other factors, such as the menstrual
cycle50 or nipple damage/duct obstruction associated with nipple
piercing,51 on the health status of the breast via measurement of
breastmilk leukocyte content.
METHODS
Study design
The study was approved by the Human Research Ethics Committee of The
University of Western Australia. Twenty-one breastfeeding dyads were recruited
for the study and provided written informed consent. The lactation spectrum
ranged from day 1 to year 4 postpartum. Breastmilk samples (5–50 ml) were
collected at the following stages of lactation: colostrum (days 1–4 postpartum,
N¼ 5), transitional milk (day 5 to week 3 postpartum, N¼ 7) or mature
breastmilk (week 4 postpartum and beyond, N¼ 51), and were collected
during any infection of the mother or the infant as well as prior and/or after
recovery (Supplementary Figure S2). The participants provided detailed
description of the symptoms of the infections, which included organ-specific
and general infections of the mother and/or the infant (Supplementary Table
S1). Infections were clinically diagnosed by the participant’s general practi-
tioner, and managed with appropriate treatment. Milk samples were aseptically
collected in the morning using an electric breast pump (Medela AG, Baar,
Switzerland) and kept in sterile polypropylene vials at B20 1C in the dark
during transportation to the laboratory. Cellular analyses were conducted
within 1–2 h of expression, while all other analyses were done in frozen
(80 1C) sample aliquots as described below. Total cells were isolated from
breastmilk as described previously.22 Total cell content and viability were
determined with a Neubauer hemocytometer (BRAND, Wertheim, Germany)
by Trypan Blue exclusion. Subsequently, cells were analyzed using FACS,
immunofluorescence staining and immunoreactivity physiological tests.
Flow cytometry
The cell suspension was distributed in vials and cells were incubated for 30 min
at 4 1C with fluorescent-labeled anti-human CD45 (Supplementary Table S2).
For leukocyte subset analysis, fluorescent-labeled antibodies against CD45,
CD3, CD4, CD8, CD19, CD56 and CD14 were combined (Supplementary
Table S2). Cells were washed twice in 3% fetal bovine serum in phosphate-
buffered saline (PBS) and incubated for 30 min at 4 1C with live/dead fixable
far-red dead cell stain (Life Technologies, Mulgrave, VIC, Australia) as per
manufacturer’s instructions. Cells were fixed in 1% paraformaraldehyde/0.7%
sucrose solution in PBS and analyzed with a FACS Calibur Flow Cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA). Further data analyses were done
using FlowJo (http://www.flowjo.com). Respective isotype controls were used
to standardize background fluorescence. A completely unstained sample was
always prepared in which propidium iodine (Sigma-Aldrich, Castle Hill, NSW,
Australia) was added to check for the cellular uniformity of the cell suspension.
In cases where this sample contained non-cellular particles (such as cellular
fragments or fat globules), propidium iodine was added in all other samples
(stained and controls) of the same cell suspension and only the cellular
component was considered in the analyses.
Immunostaining
The cell suspension was fixed in 1% paraformaraldehyde/0.7% sucrose solution
in PBS. Cytospins on glass slides were generated using Shandon Cytospin 3
(Shanton) centrifuge at 40.7 g for 4 min, and incubated with fluorescent-
labeled anti-human CD45 antibody (Supplementary Table S2) for 1 h at room
temperature under humid conditions. Cytospins were washed in PBS,
incubated with 406-diamidino-2-phenylindole (1:100) for 15 min, mounted
in Cytomation mounting medium (Dako Australia, Campbellfield, VIC,
Australia) and observed using a Nikon A1Si confocal microscope. Data were
collected using the Nikon NIS Elements software package (Melville, NY, USA).
Immunoreactivity of milk leukocytes
In cases of very high breastmilk leukocyte content (60–90% of total cells),
typically when the mother was diagnosed with mastitis, a subsample of the
isolated live breastmilk leukocytes was cultured in U-bottom cell culture
96-well plates (Sarstedt, Numbrecht, Germany) at 500 000 cells per well in
RPMI basic medium (Gibco, Grand Island, NY, USA) supplemented with 5%
human serum and 5% antibiotic/antimycotic (Invitrogen). Six to eight
statistical replicates (wells) were created per condition, which included (1)
control (cell suspension in the above medium), (2) antigen effect (addition of
1ml per well of CEF peptide pool, Cat No. 3615-1, Mabtech, Nacka Strand,
Sweden) and (3) PHA effect (addition of 5ml per well of Leucoagglutinin
PHA-L, Cat No. L-4144, Sigma-Aldrich). Cells were incubated at 37 1C and 5%
CO2 for 5 days before (a) removal of a 50-ml aliquot of culture supernatant and
storage at 20 1C for cytokine analyses, and (b) addition of BrdU-labeling
solution for measurement of cell proliferation using a BrdU Cell Proliferation
enzyme-linked immunosorbent assay kit (Colorimetric, Roche, Dee Why,
NSW, Australia, Cat. No. 11 647 229 001) according to the manufacturer’s
instructions.
Cytokine measurements
Cytokines were determined in culture supernatants obtained from the
immunoreactivity tests using the BD Cytometric Bead Array Cytokine Kit
(Becton Dickinson) for seven cytokines (IL-2, IL-4, IL-6, IL-10, IL-17A, tumor
necrosis factor-a and interferon-g), following the manufacturer’s instructions
and assaying samples in duplicate in 1:1 dilution. A five-parameter logistic
model was used to convert the bead fluorescence intensities to analyte
concentrations.
Enzyme-linked immunosorbent assay
Immunoglobulin (sIgA, IgG and IgM) and lactoferrin breastmilk concentra-
tions were measured by enzyme-linked immunosorbent assay in defatted
acellular sample aliquots stored at 80 1C, as described previously.52 The 96-
well microtitre plates were coated with 250ml per well of anti-human sIgA
(37 1C, 1 h), IgG or IgM (4 1C, overnight) (Supplementary Table S2).
Subsequently, 200ml per well of blocking solution (0.05% Tween-20/PBS
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containing 1 mg ml1 BSA for sIgA/lactoferrin; skim bovine milk for IgG/IgM)
was added for 30 min. The stored breastmilk samples were thawed to room
temperature and diluted in 0.05% Tween-20/PBS 5000 times for sIgA, 600
times for IgG and IgM, and 50 000 times for lactoferrin. After washing (0.05%
Tween-20/PBS) three times, 200ml per well of standard, sample or control were
added in duplicates for an 1-h incubation at 37 1C. Washing was followed by
addition of 200ml per well of secondary antibody and incubation for 1 h at
37 1C (Supplementary Table S2). The dilution of the secondary antibody for
sIgA/lactoferrin was done in 0.05% Tween-20/PBS containing 1 mg ml1 BSA,
whereas for IgG/IgM in 0.05% Tween-20/PBS. In the IgM assay, incubation
with the secondary antibody was followed by three washes and subsequent
incubation with 200ml per well of NeutrAvidin-HRP for 1 h at 37 1C
(Supplementary Table S2). After secondary/tertiary antibody incubation,
washing and rinsing with deionised water, 200ml per well of color reagent
were added and incubated in the dark at room temperature for 10–30 min. The
color reaction was stopped by addition of 100ml per well of 3 M sulfuric acid
and the plate was read at 405 nm using a BioTek PowerWave X5 plate reader
(BioTek, Winooski, VT, USA). The recovery of a known amount of sIgA, IgG,
IgM or lactoferrin added to milk samples was on average 100.6±2.9%. The
inter-assay coefficient of variation was on average 3.6%.
Statistical analyses
Statistical analyses were performed in R 2.9.0 153 using the base packages
and libraries lattice,54 nlme55 and multcomp.56 Results are presented as
mean±s.e.m. unless otherwise specified, and Po0.05 was considered
significant. Linear mixed effects models were used to determine which of the
response variables (leukocyte content (% of total cells), leukocyte content (per
ml milk), total and viable cell contents (per ml milk), cell viability (% viable
cells of total cells), sIgA, IgG, IgM and lactoferrin) were affected by milk type,
lactation stage, health status of the mother/infant dyad and breastfeeding status
(exclusive versus non-exclusive). All models included a grouping factor of dyad
and a random effect of different baseline levels for each dyad. Where health
status was included in a model, ‘healthy’ was considered to be the reference
level. To determine whether data transformation was required, comparisons
were made between raw data, square root-transformed data and natural log-
transformed data models. After fitting the univariate model for each predictor,
diagnostic plots (fitted values versus standardised residuals; qq-plot of
residuals) were examined. In cases where a transformation was obviously
superior, this was used for all covariate models. Owing to the measured zeroes
obtained for leukocyte content (% and per ml milk) of some samples, these
variables were transformed using the additive constant 0.5 for both the square
root and the log transformations.57 Differences between colostrum, ‘healthy’
and ‘infection’ samples were tested for with a three-level categorical predictor
of milk type. Differences between ‘healthy’ samples and each of the infection
types were tested using a five-level factor (‘healthy’, ‘breast’, ‘baby’, ‘cold’ and
‘other’), with the colostrum samples omitted. Differences between pre- and
post-infection ‘healthy’ samples were tested where data were available (n¼ 7)
by classifying ‘healthy’ as a two-level factor (‘pre’ and ‘post). To determine
whether there were interactions between the health status of the dyad and
either lactation stage (age in weeks) or exclusive breastfeeding (yes/no) in
mature breastmilk, interaction models were considered for each of these
covariates separately. Infection status was considered as a two-level factor
(‘healthy’ and ‘infection’). Models were selected using backwards stepwise
methods, starting with the main effectsþ interaction model. Where the
interaction was significant, all main effects were retained in the model.
For the lactation stage model, analysis was restricted to records where the
baby was under 60 weeks of age (N¼ 46 records, for 15 participants), due to
the scarcity of data beyond this point. The effect of viral antigens and PHA on
proliferation rate in leukocyte cultures generated from two samples of mastitic
breastmilk was also assessed using linear mixed effects models. Separate models
were used for each response variable, with replicate as the grouping variable
and a random effect of different baseline effects per replicate. Tukey’s HSD test
was used to test all pairwise comparisons between the three treatments
(control, viral antigen and PHA). Multivariate patterns in the immune markers
(sIgA, IgG, IgM and lactoferrin) and three cellular measures (total cell and
leukocyte contents, % leukocytes) were investigated analytically using singular
value decomposition principal components analysis on scaled and centered
data and graphically using biplots. This enabled comparisons between the
conditions that were seen infrequently in this study.
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